News

Professor Zhang Ge, Associate Dean (Research), has successfully secured a grant of HK$1.8 million from the Pneumoconiosis Compensation Fund Board for supporting a project entitled “A next-generation CTGF inhibitors to suppress pulmonary fibrosis in pneumoconiosis”. This project, led by Professor Zhang, is a collaborative effort of researchers from SCM, The Chinese University of Hong Kong, Shenzhen University General Hospital and The Second Affiliated Hospital of Shantou University Medical College.

The project aims to address the limitations of current pulmonary fibrosis medicines, particularly the limited targeted efficacy, and to advance the clinical translation of a new generation of connective tissue growth factor (CTGF) inhibitors (Apc003OA). The joint research team hopes to develop a proprietary, long-acting CTGF aptamer drug that can provide safer and more effective anti-fibrotic treatment for patients with pneumoconiosis.

Professor Zhang remarked, “The School is committed to collaborative research and has consistently worked with national and international research teams to develop new research projects. We hope to bring new hope to patients by advancing innovative anti-fibrotic therapies.”